Enterprise Bank & Trust Co Takes $239,000 Position in Cencora, Inc. (NYSE:COR)

Enterprise Bank & Trust Co purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,063 shares of the company’s stock, valued at approximately $239,000.

A number of other large investors have also recently modified their holdings of the business. Cooper Financial Group boosted its position in shares of Cencora by 8.1% during the 4th quarter. Cooper Financial Group now owns 3,211 shares of the company’s stock valued at $721,000 after acquiring an additional 240 shares during the last quarter. Wedmont Private Capital boosted its position in shares of Cencora by 33.1% during the 4th quarter. Wedmont Private Capital now owns 2,453 shares of the company’s stock valued at $579,000 after acquiring an additional 610 shares during the last quarter. City State Bank boosted its position in shares of Cencora by 19.3% during the 4th quarter. City State Bank now owns 618 shares of the company’s stock valued at $139,000 after acquiring an additional 100 shares during the last quarter. Trust Co. of Toledo NA OH lifted its position in Cencora by 32.6% in the 4th quarter. Trust Co. of Toledo NA OH now owns 1,358 shares of the company’s stock worth $305,000 after buying an additional 334 shares during the last quarter. Finally, Czech National Bank lifted its position in Cencora by 7.0% in the 4th quarter. Czech National Bank now owns 38,025 shares of the company’s stock worth $8,543,000 after buying an additional 2,489 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the transaction, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,696 shares of company stock valued at $22,862,734. 15.80% of the stock is currently owned by corporate insiders.

Cencora Stock Down 0.2 %

COR stock traded down $0.47 during midday trading on Monday, hitting $235.72. The stock had a trading volume of 459,054 shares, compared to its average volume of 1,248,639. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business has a 50-day moving average of $237.77 and a two-hundred day moving average of $233.48. Cencora, Inc. has a 52-week low of $214.77 and a 52-week high of $253.27. The firm has a market cap of $45.56 billion, a price-to-earnings ratio of 31.39, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.93%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is 29.29%.

Analyst Ratings Changes

COR has been the subject of a number of recent research reports. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Wells Fargo & Company lowered their price objective on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday, December 13th. Evercore ISI boosted their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.